Header Logo

Connection

Alan Go to Registries

Back to Details
This is a "connection" page, showing publications Alan Go has written about Registries.
Alan Go
Connection Strength
3.623
Registries
  1. Coronary artery bypass grafting and percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardiothorac Surg. 2015 May; 47(5):e193-8.
    View in: PubMed
    Score: 0.436
  2. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013 Aug 21; 310(7):699-705.
    View in: PubMed
    Score: 0.388
  3. Comparative effectiveness of coronary artery bypass grafting and percutaneous coronary intervention for multivessel coronary disease in a community-based population with chronic kidney disease. Am Heart J. 2013 May; 165(5):800-8, 808.e1-2.
    View in: PubMed
    Score: 0.378
  4. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke. 2012 Oct; 43(10):2788-90.
    View in: PubMed
    Score: 0.361
  5. Predicting short-term outcomes after transcatheter aortic valve replacement for aortic stenosis. Am Heart J. 2023 02; 256:60-72.
    View in: PubMed
    Score: 0.184
  6. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators. J Am Heart Assoc. 2017 Nov 09; 6(11).
    View in: PubMed
    Score: 0.130
  7. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. J Am Coll Cardiol. 2017 Sep 12; 70(11):1325-1335.
    View in: PubMed
    Score: 0.129
  8. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 10 11; 134(15):1122-1124.
    View in: PubMed
    Score: 0.121
  9. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016 Apr; 174:29-36.
    View in: PubMed
    Score: 0.114
  10. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):393-402.
    View in: PubMed
    Score: 0.110
  11. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul; 170(1):141-8, 148.e1.
    View in: PubMed
    Score: 0.108
  12. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. Am Heart J. 2014 Aug; 168(2):160-7.
    View in: PubMed
    Score: 0.102
  13. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014 May 20; 129(20):2005-12.
    View in: PubMed
    Score: 0.101
  14. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014 May; 167(5):735-42.e2.
    View in: PubMed
    Score: 0.100
  15. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013 Feb 05; 127(5):569-74.
    View in: PubMed
    Score: 0.093
  16. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J. 2011 Oct; 162(4):606-612.e1.
    View in: PubMed
    Score: 0.085
  17. Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent). Circ Cardiovasc Interv. 2010 Jun 01; 3(3):230-5.
    View in: PubMed
    Score: 0.077
  18. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2020 08; 226:85-93.
    View in: PubMed
    Score: 0.039
  19. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2019 12; 12(12):e007612.
    View in: PubMed
    Score: 0.038
  20. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. Am Heart J. 2019 07; 213:81-90.
    View in: PubMed
    Score: 0.036
  21. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439.
    View in: PubMed
    Score: 0.035
  22. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart. 2018 11; 104(22):1850-1858.
    View in: PubMed
    Score: 0.034
  23. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circ Arrhythm Electrophysiol. 2017 Nov; 10(11).
    View in: PubMed
    Score: 0.032
  24. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017 07 01; 3(3):192-197.
    View in: PubMed
    Score: 0.032
  25. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clin Cardiol. 2017 Sep; 40(9):746-751.
    View in: PubMed
    Score: 0.031
  26. Report of the National Heart, Lung, and Blood Institute Working Group: An Integrated Network for Congenital Heart Disease Research. Circulation. 2016 Apr 05; 133(14):1410-8.
    View in: PubMed
    Score: 0.029
  27. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016 06; 129(6):592-599.e1.
    View in: PubMed
    Score: 0.029
  28. Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. Clin Cardiol. 2016 Feb; 39(2):119-25.
    View in: PubMed
    Score: 0.029
  29. The Contemporary Safety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral Endovascular Interventions in the Treatment of Symptomatic Peripheral Arterial Disease. Circulation. 2015 Nov 24; 132(21):1999-2011.
    View in: PubMed
    Score: 0.028
  30. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015 Jun 30; 65(25):2691-8.
    View in: PubMed
    Score: 0.028
  31. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013 Aug 13; 128(7):721-8.
    View in: PubMed
    Score: 0.024
  32. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):461-9.
    View in: PubMed
    Score: 0.024
  33. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA. 2013 May 15; 309(19):2025-34.
    View in: PubMed
    Score: 0.024
  34. Longitudinal study of implantable cardioverter-defibrillators: methods and clinical characteristics of patients receiving implantable cardioverter-defibrillators for primary prevention in contemporary practice. Circ Cardiovasc Qual Outcomes. 2012 Nov; 5(6):e78-85.
    View in: PubMed
    Score: 0.023
  35. Glycemic response to newly initiated diabetes therapies. Am J Manag Care. 2007 Nov; 13(11):598-606.
    View in: PubMed
    Score: 0.016
  36. Patient sex and quality of ED care for patients with myocardial infarction. Am J Emerg Med. 2007 Nov; 25(9):996-1003.
    View in: PubMed
    Score: 0.016
  37. Exploring secular trends in the likelihood of receiving treatment for end-stage renal disease. Clin J Am Soc Nephrol. 2007 Jan; 2(1):81-8.
    View in: PubMed
    Score: 0.015
  38. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Commitee to Develop Data Standards on Atrial Fibrillation). J Am Coll Cardiol. 2004 Jul 21; 44(2):475-95.
    View in: PubMed
    Score: 0.013
  39. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation. 2004 Jun 29; 109(25):3223-43.
    View in: PubMed
    Score: 0.013
  40. Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women. J Am Coll Cardiol. 2001 Nov 01; 38(5):1297-301.
    View in: PubMed
    Score: 0.011
  41. Treatment and outcomes of left bundle-branch block patients with myocardial infarction who present without chest pain. National Registry of Myocardial Infarction 2 Investigators. J Am Coll Cardiol. 2000 Sep; 36(3):706-12.
    View in: PubMed
    Score: 0.010

© 2024 Kaiser Permanente